Rexahn Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Partnerships
  • Product Pipeline
    • Overview
    • RX-3117
    • RX-5902
    • RX-0301
    • Publications
  • Clinical Trials
    • Overview
    • Metastatic Pancreatic Cancer Clinical Trial
    • Advanced Bladder Cancer Clinical Trial
    • Triple Negative Breast Cancer Clinical Trial
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations
    • Posters
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Posters
  • Events

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Jun 17, 2020

Rexahn to Explore Strategic Alternatives

Sep 24, 2019

Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

Aug 7, 2019

Rexahn Announces Move to Nasdaq

May 28, 2019

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

May 13, 2019

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

Apr 16, 2019

Rexahn Effects 1-for-12 Reverse Stock Split

Apr 12, 2019

Rexahn Announces Reverse Stock Split

Apr 10, 2019

Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

Mar 27, 2019

Rexahn Pharmaceuticals Reports 2018 Financial Results

Mar 8, 2019
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...31
Rexahn Pharmaceuticals, Inc.
© 2020 Rexahn Pharmaceuticals, Inc.
All Rights Reserved.
  • About
  • Overview
  • Management Team
  • Board of Directors
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Partnerships
  • Product Pipeline
  • Overview
  • RX-3117
  • RX-5902
  • RX-0301
  • Publications
  • Clinical Trials
  • Overview
  • Metastatic Pancreatic Cancer
  • Advanced Bladder Cancer
  • Triple Negative Breast Cancer
  • Expanded Access Policy
  • News & Media
  • Press Releases
  • Presentations
  • Posters
  • Events
  • Investors
  • Overview
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Contact
Privacy Policy Disclaimer Sitemap